Why this $6.3-billion money manager is buying Eli Lilly and selling a software firm

Guardian i3 Global Dividend Growth Fund returned 3.17% year-to-date and 5.63% over one year, with 3- and 5-year annualized returns of 10.54% and 18.36% (total returns net of fees as of Feb. 28). Portfolio manager Fiona Wilson urges investors not to trade headlines amid geopolitically driven volatility and is buying ASML (near-90% lithography market share; raised dividend 17% in 2025 and €12bn buyback), Eli Lilly (revenue up ~45% YoY driven by GLP-1 drugs and guidance ~25% growth for 2026), and Amphenol (acquired CommScope connectivity business for $10.5bn); she trimmed Wolters Kluwer due to AI-driven margin risks and leadership change.

Analysis

Volatility-driven positioning is the dominant theme — income and capital-return stories are being used as ballast rather than pure growth exposure. That makes sense short-term, but it also creates a cross-cycle trade: companies that can convert large, lumpy capex backlogs into predictable free cash flow (and sustain buybacks/dividends) will compound returns through a bout of macro uncertainty while peers face margin compression.

Second-order winners are not just the headline equipment and drug makers but niche suppliers and service providers embedded in those capex chains — precision optics, speciality gases/metrology for chipmakers, and high-margin connector/component tiers for hyperscale datacentres. Conversely, legacy recurring-revenue providers with low differentiation face asymmetric downside as AI lowers marginal delivery costs and forces re-pricing; that structurally compresses margins faster than headline multiples imply.

Key risks: a rapid re-pricing of semiconductor equipment orders if hyperscalers slow AI server adds (3–9 month trigger), export-control escalation that reroutes demand, and regulatory/payer pushback on GLP-1 pricing that can shave growth trajectories materially over 6–18 months. Acquisition/integration risk (large deals in connectivity/hardware) creates a mid-term 12–24 month earnings cliff if synergies miss and leverage rises.

The market consensus underweights execution and policy tail-risk while over-weighting durable “moats” in sectors being disrupted by AI-enabled deflation in services. That argues for concentrated, hedged exposure to franchise businesses with visible cash conversion and for option structures that cap downside while leaving upside to a potentially sharp re-acceleration in capex or product adoption.

Key Decisions for Investors

• Long ASML via 12–18 month call spread: buy 1x ATM 12–18m call, sell 1x 30% OTM 12–18m call to fund. Rationale: capture order-conversion upside while capping premium paid. Target return 1.5–3x premium if EUV/order conversion continues; max loss = paid premium. Size: 2–4% of equity sleeve.
• Pair trade — long AMPHENOL (APH) vs short COMM SIZING (COMM) 6–12 months, equal notional: long to express data-centre connectivity re-rating, short to express residual integration and balance-sheet pressure in legacy network vendors. Risk: integration failure or unexpected cyclical hit to both; expected asymmetric payoff 20–50% to the long leg if cross-sell synergies materialize.
• GLP-1 pair — long ELI LILLY (LLY) / short NOVO NORDISK (NVO) 12 months: express conviction in execution and pipeline breadth while hedging class/regulatory risk. Use 1:0.7 notional to reduce exposure to broad class moves. Target 15–35% net return if LLY sustains premium pricing and pipeline milestones; risk of regulatory pricing action that hurts both.
• Defensive income & convexity — buy AAPL equity and sell near-term (3 month) 10–15% OTM calls (covered-call) while allocating 0.5–1% of portfolio to 3-month S&P 5% OTM puts as tail insurance. Rationale: generate yield to lower cost basis in high-quality tech exposure while keeping a cheap asymmetric hedge against headline-driven drawdowns.